Midazolam Accord

Midazolam, the active ingredient in Midazolam Accord, is a benzodiazepine presented as a sterile injectable for intramuscular, intravenous and rectal use. It provides rapid sedation, anxiolysis, muscle relaxation and anticonvulsant activity for procedural sedation, induction of anesthesia, anxiety relief and status epilepticus in hospital settings.

GNH USA supplies Midazolam Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Midazolam is a benzodiazepine that acts on the central nervous system to produce sedation and seizure control.

Procedural sedation: enables quick, controllable sedation for minor surgical or diagnostic procedures. Induction of anesthesia: facilitates smooth transition to general anesthesia before surgery. Anxiety relief: reduces acute pre‑operative or procedural anxiety. Status epilepticus: terminates ongoing seizures when first‑line therapies are insufficient.

Midazolam may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Drowsiness - Dizziness - Fatigue - Anterograde amnesia - Mild hypotension

Serious or Rare Side Effects: - Respiratory depression - Paradoxical agitation or aggression - Severe hypotension or cardiovascular collapse - Cardiac arrhythmias - Allergic reactions such as rash or anaphylaxis

When using Midazolam, clinicians should observe specific safety measures.

Assess respiratory function: monitor oxygen saturation and ventilation. Monitor blood pressure: watch for hypotensive episodes. Use caution in the elderly: increased sensitivity may require dose adjustment. Avoid abrupt discontinuation: taper to prevent withdrawal symptoms. Contraindicated in severe respiratory depression: do not administer to patients with compromised breathing. Store at controlled room temperature: keep in original packaging, protect from moisture and light.

Midazolam can interact with other substances that affect the central nervous system.

Major Interactions (Avoid): - Opioids: additive respiratory depression. - Other benzodiazepines: excessive sedation. - Alcohol: heightened CNS depression.

Moderate Interactions (Monitor Closely): - Ketoconazole and other strong CYP3A4 inhibitors: increase plasma levels. - Macrolide antibiotics (e.g., erythromycin): may raise drug concentration. - Carbamazepine and other CYP3A4 inducers: reduce therapeutic effect.